Skip to main content

Table 3 hATTR-PN patients clinical characteristics

From: Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study

CharacteristicsPatients
No. Subjects (no. visits)733 (2913)
Age at onset, years
 Mean ± SD38.1 ± 12.6
 Median (IQR)34 (29–44)
Late-onset, n (%)116 (15.8)
Disease duration at THAOS enrolment, years
 Mean ± SD4.5 ± 4.8
Age at diagnosis, years
 Mean ± SD39.4 ± 12.9
 Median (IQR)35 (30–45)
Disease mPND stage, n (%)
 stage I537 (73.3)
 stage II141 (19.2)
 stage IIIa22 (3)
 stage IIIb12 (1.6)
 stage IV21 (2.9)
Disease Coutinho stage, n (%)
 stage 1678 (92.5)
 stage 234 (4.6)
 stage 321 (2.9)
Visit, n
 1733
 2641
 3526
 4419
 5298
 6187
 788
 816
 95
Treated, n (%)637 (86.9)
  1. Clinical characteristics measured at THAOS enrolment or first EQ-5D-3L response; Treatment variable status measured across follow-up; SD denotes standard deviation, IQR interquartile range